Author Archive | Umesh Laddi

Metallic molecule offers real-time monitoring of amyloid plaques in patients with Alzheimer’s

   A metallic molecule being studied at Rice University begins to glow when bound to amyloid protein fibrils of the sort implicated in Alzheimer’s disease. When triggered with ultraviolet light, the molecule glows much brighter, which enables real-time monitoring of amyloid fibrils as they aggregate in lab experiments. Rice chemist Angel Martí said such a […]

Continue Reading

Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

In continuation of my update on everolimus The targeted therapy everolimus may be safely combined with R-CHOP for new, untreated diffuse large B-cell lymphoma according to the results of a pilot study by Mayo Clinic researchers published in the Lancet Haematology. R-CHOP is a combination of drugs used to treat lymphoma. The combination includes rituximab, cyclophosphamide, […]

Continue Reading

Urolithin A found in pomegranates may improve muscle strength and endurance during aging

In continuation of my update on Urolithin A Amazentis SA, an innovative life sciences company applying scientific breakthroughs in nutrition to manage health conditions linked to aging, announced today a collaborative publication in Nature Medicine with the École Polytechnique Fédérale de Lausanne (EPFL), demonstrating that the Company’s lead product candidate, urolithin A, improves mitochondrial and muscle function, resulting […]

Continue Reading

Leukemia drug increases brain dopamine, lowers toxic proteins linked to Parkinson’s or dementia

My updates on  nilotinib A small phase I study provides molecular evidence that an FDA-approved drug for leukemia significantly increased brain dopamine and reduced toxic proteins linked to disease progression in patients with Parkinson’s disease or dementia with Lewy bodies. Dopamine is the brain chemical (neurotransmitter) lost as a result of death of dopamine-producing neurons in […]

Continue Reading

New research shows how cholesterol medicine has beneficial effect on immune defence system

In continuation of my update on simvastatin,   The cholesterol medicine simvastatin, which is one of the most commonly used pharmaceuticals in the world, also has a beneficial effect on the immune defence system with regard to diseases such as type 1 diabetes, multiple sclerosis and rheumatoid arthritis. Danish researchers have now explored why this is so, […]

Continue Reading

Transplant drug rapamycin may reduce nerve damage, neuropathic pain after spinal cord injury

In continuation of my update on rapamycin New research in mice indicates that a drug commonly used to suppress the immune system in recipients of organ transplants may also reduce tissue damage and neuropathic pain after spinal cord injury. The findings are published in the Journal of Orthopaedic Research.    rapamycin Rapamycin, which is an inhibitor […]

Continue Reading